Abemaciclib for sarcoma with specific cell-growth gene changes
Treatments studied
Part of Cancer, Eyes & vision clinical trials.
This trial tests abemaciclib (a cancer medicine) in adults with advanced, unresectable bone or soft-tissue sarcoma that has certain gene changes in the “CDK pathway.” It aims to shrink tumors or slow growth in people whose tumors match the study’s biomarker and lab requirements.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older and can sign the study’s consent forms.
- Your cancer is a type like soft-tissue sarcoma, osteosarcoma, chordoma, or certain chondrosarcomas, and it is metastatic or locally advanced and cannot be removed by surgery.
- Your tumor test shows a CDK pathway change (for example, CDK4/6 or cyclin gene amplification, or CDKN2A/2B loss).
- Your tumor is “Rb positive” on a central lab test, using saved tumor tissue.
- Your disease can be measured on scans, and it progressed within 6 months (or was newly diagnosed within 6 months).
- You are well enough for treatment: generally ECOG 0–1, sufficient blood counts and organ function, and you meet required washout times after chemo/radiation/surgery.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 study tests two anti-cancer medicines (anlotinib and catequentinib) for people with certain advanced soft-tissue sarcomas, including alveolar soft part sarcoma, synovial sarcoma, and leiomyosarcoma. It is designed for tumors that cannot be removed and that have either grown despite treatment or no longer respond to standard options.
This trial tests whether adding the targeted drug abemaciclib to standard chemotherapy (gemcitabine) works better against certain soft tissue sarcomas. It is for people whose tumors have a normal Rb gene, which may help the drug work.
This Phase 2 study tests abemaciclib, a targeted cancer medicine, in people with advanced solid tumors that have specific gene changes related to cyclin D or CDK4/6. The goal is to see how well it controls tumors when standard treatments don’t work or aren’t available.
This trial tests a combination of the targeted drug abemaciclib and radiation therapy before surgery for people with a specific type of liposarcoma. The goal is to see if this combination can shrink the tumor and help make surgery more effective.
This trial tests whether a targeted therapy (abemaciclib) combined with focused radiation (SBRT) to a bone tumor can help people with advanced breast cancer. It is for patients whose cancer is hormone receptor positive and HER2 negative, and who will continue abemaciclib after radiation.
This trial tests whether adding a targeted therapy (abemaciclib) to standard chemotherapy before surgery can shrink tumors and improve outcomes in hormone-positive, HER2-negative early breast cancer. It also uses a genetic test (Oncotype DX) to help guide surgical choices.
Hear when a new Chondrosarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.